Evaluation of combined pharmaceutical medicines used in hypopotassemia

Abstract

Introduction. The fixed dose combined pharmaceutical medicine represent an association of two or more drug substances, using in several branches, including the hypopotassemia treatment (potassium concentration in the blood plasma is below 3.5 mmol/l). For example: Panangin, Asparcam, Antikircel. The single-component therapy with potassium chloride, potassium iodide or other potassium salts ensures the essential pharmaco-therapeutic in up to 50% of the medical treatment cases, therefore it is less effective, than using of combined pharmaceutical medicine, that shows better results in hypopotassemia. In particular, those combinations of pharmaceutical substances are plausible which achieve not only the removal of the hypopotassemia symptoms (cramps, cardiac arrhythmias), but also the causal treatment. Aim of the study. Evaluation of the combined pharmaceutical products market used in hypopotassemia in the Republic of Moldova (RM). Materials and methods. The analysis of the pharmaceutical market of RM, the study of the State Nomenclature of Medicines. Results. As a result of the detailed analysis of the pharmaceutical market in the RM it was determined that the basic producters of the combined medicines, using in the treatment of hypopotassemia, are Romania - 42%, Ukraine - 21%, Russia - 17%, Germany - 9%, US - 6 %, Hungary - 5%. Unfortunately, the monocomponent potasium medicines predominate (70%) on the pharmaceutical market of the RM, which provides only a daily dose of this electrolyte. There is not any native combined medicine in RM. Basing on this fact, it is proposed to elaborate a new combined pharmaceutical product containing potassium aspartate, magnesium aspartate, potassium orotate and spironolactone, which will be able to ensure adequate causal treatment in hypopotassemia due to stopping of the potassium losses (renal or extrarenal) and regulation of metabolic disorders, which generates the normalization of potassium potential in cells. Conclusions. The actuality and usefulness have demonstrated the necessary of the research initiating to elaborate the native combined pharmaceutical product, which would be accessible, effective, convenient and low in toxicity